Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fedovapagon TQT study in healthy volunteers
NCT02537288Phase 1Completed
- Sponsor
- Vantia Therapeutics
- Start
- Oct 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fedovapagon in nocturia (4 arms), sponsored by Vantia Therapeutics. Primary endpoint: Time-matched change from baseline in QTc, placebo-adjusted and corrected for heart rate. Started Oct 2015; status: completed.
02
Drugs
fedovapagon
03
Conditions
nocturia
Beyond the preview
Go deeper on NCT02537288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02537288.